Latest Neuronetics Stories

Study Participants Experienced Improvement in Pain and Well-Being that Persisted Through One Year SAN DIEGO, March 19, 2013 /PRNewswire/ -- New data released today at the annual meeting of the American Academy of Neurology show that transcranial magnetic stimulation (TMS) administered using the NeuroStar TMS Therapy System® significantly reduced pain-related symptoms in patients with Major Depressive Disorder (MDD), with improvement sustained through one year. Pain-related symptoms...

While powerful magnetic stimulation of the frontal lobe of the brain can alleviate symptoms of depression, those receiving the treatment did not report effects on sleep or arousal commonly seen with antidepressant medications, researchers say. "People's sleep gets better as their depression improves, but the treatment doesn't itself cause sedation or insomnia." said Dr. Peter B. Rosenquist, Vice Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia at...

PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Neuronetics, Inc., a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric conditions, announced today that its NeuroStar TMS Therapy(®) System has been awarded the prestigious Phoenix 2012 Most Promising New Product Award at the 19(th) annual Phoenix Conference. Phoenix, the Medical Device and Diagnostic Conference for Chief Executive Officers, presents awards each...

TMS NeuroHealth Centers in Tysons Corner was recently featured in a story aired on WJLA-TV on depression treatments in the Washington DC metro area. McLean, Virginia (PRWEB) August 08, 2012 TMS therapy is a newly FDA cleared form of treatment for depression. The story touched on two of TMS NeuroHealth Centers’ patients and how TMS therapy changed their lives. Their story left touching testimonials for all those suffering from depression and provided hope for treatment. TMS therapy...

Naturalistic study shows transcranial magnetic stimulation works for depression in real-life clinical practice settings In one of the first studies to look at transcranial magnetic stimulation (TMS) in real-world clinical practice settings, researchers at Butler Hospital, along with colleagues across the U.S., confirmed that TMS is an effective treatment for patients with depression who are unable to find symptom relief through antidepressant medications. The study findings are published...

MALVERN, Pa., June 4, 2012 /PRNewswire/ -- Neuronetics, Inc. announced today the receipt of CE Mark approval for its NeuroStar TMS Therapy® System for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to receive satisfactory improvement from antidepressant medications. The decision is based on data from five studies, collectively representing the largest clinical data set for a therapeutic use of TMS, that demonstrate the safety and efficacy of...

Percentage of patients reporting a return to normal activities more than tripled following treatment with NeuroStar TMS Therapy New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy® achieved significant improvements in both depression symptoms and in quality of life measurements. Overall, 58 percent of...

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy® achieved significant improvements in both depression symptoms and in quality of life measurements. Overall, 58 percent of patients achieved a positive response to NeuroStar TMS therapy, with 37...

LONDON, Feb. 28, 2012 /PRNewswire/ -- Based on its recent analysis of the neuro-psychiatric devices market, Frost & Sullivan recognises Brainsway with the 2012 Global Frost & Sullivan New Product Innovation Award. Brainsway's cutting-edge deep Transcranial Magnetic Stimulation (dTMS) is the only non-invasive technique that can be used for the treatment of depression and other neuro-psychiatric disorders without causing any significant side effects. "The system has shown...

SAN FRANCISCO, Sept. 20, 2011 /PRNewswire/ -- Lenox Hill TMS Psychiatric Associates, a recognized New York provider of transcranial magnetic stimulation (TMS) therapy, today announced the opening of their new San Francisco TMS Center in the Medical Arts Building at 2000 Van Ness Avenue in Nob Hill. The Center was opened in response to a shortage of TMS-providers in San Francisco. TMS therapy is a U.S. Food and Drug Administration (FDA)-cleared system that uses targeted magnetic pulses on...